MBK Partners-Backed Osstem Implant Undergoes Organizational Restructuring Amid Workforce Reallocation

According to The Fact, MBK Partners' portfolio company Osstem Implant recently initiated organizational restructuring involving workforce reallocation and job function transitions, sparking controversy over management practices at PE-backed enterprises. The move reflects broader scrutiny of private equity firms' cost-cutting strategies following recent corporate controversies. Separately, Macquarie is advancing its acquisition of Gavia, with the deal valued at 627.6 billion Korean won and targeting delisting.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments